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Abstract 
Gastric cancer (GC) is a major cause of global cancer mortality. Genetic variations in DNA repair 
genes can modulate DNA repair capability and, consequently, have been associated with risk of 
developing cancer. We have previously identified a T to C point mutation at nucleotide 889 
(T889C) in DNA polymerase beta (POLB) gene, a key enzyme involved in base excision repair in 
primary GCs. The purpose of this study was to evaluate the mutation and expression of POLB in a 
larger cohort and to identify possible prognostic roles of the POLB alterations in GC. Primary GC 
specimens and their matched normal adjacent tissues were collected at the time of surgery. DNA, 
RNA and protein samples were isolated from GC specimens and cell lines. Mutations were de-
tected by PCR-RFLP/DHPLC and sequencing analysis. POLB gene expression was examined by 
RT-PCR, tissue microarray, Western blotting and immunofluorescence assays. The function of the 
mutation was evaluated by chemosensitivity, MTT, Transwell matrigel invasion and host cell re-
activation assays. The T889C mutation was detected in 18 (10.17%) of 177 GC patients. And the 
T889C mutation was associated with POLB overexpression, lymph nodes metastases and poor 
tumor differentiation. In addition, patients with- the mutation had significantly shorter survival time 
than those without-, following postoperative chemotherapy. Furthermore, cell lines with T889C 
mutation in POLB gene were more resistant to the treatment of 5-fluorouracil, cisplatin and epi-
rubicin than those with wild type POLB. Forced expression of POLB gene with T889C mutation 
resulted in enhanced cell proliferation, invasion and resistance to anticancer drugs, along with 
increased DNA repair capability. These results suggest that POLB gene with T889C mutation in 
surgically resected primary gastric tissues may be clinically useful for predicting responsiveness to 
chemotherapy in patients with GC. The POLB gene alteration may serve as a prognostic biomarker 
for GC. 
Key words: DNA polymerase beta (POLB); gastric cancer; DNA Repair; point mutation; chemotherapy. 
Introduction 
Gastric cancer (GC) is the second leading cause 
of cancer-related deaths worldwide [1]. It remains 
difficult to cure, primarily due to lack of reliable 
screening markers and advanced disease when diag-
nosed. Even patients who present the most favorable 
condition at diagnosis and subsequently undergo 
curative surgical resection often die of recurrent dis-
ease [2]. Genetic variations in DNA repair genes can 
modulate DNA repair capability and, consequently, 
have been associated with the risk of developing 
cancer [3]. DNA polymerase beta (POLB) is a DNA re-
pair polymerase involved in base-excision repair 
(BER), and recombination and drug resistance [4-6]. 
Thirty percent of all tumors reported to date harbor 
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mutations in the POLB gene [7]. Aberrant POLB ex-
pression resulted in an increased rate of spontaneous 
mutagenesis and a highly mutagenic tolerance phe-
notype [8, 9]. POLB gene mutation and overexpres-
sion have been reported in various cancers [10-14]. In 
our previous studies, we identified a novel homozy-
gous T to C point mutation at nucleotide 889 (T889C) 
in POLB gene (GenBank Acc# M13140.1) from human 
primary GC. This mutation resulted in a substitution 
of the amino acid at 259 from Leucine to Serine in 
protein [15]. In the present work, we examined the 
T889C mutation and expression of POLB in a large 
cohort of GC patients with integral follow-up records, 
and analyzed the relationship between aberrant POLB 
expression and patients’ clinicopathological features. 
Materials and Methods 
Cell lines and tissue samples 
Eight human GC cell lines AGS, N-87, SUN1, 
SUN5, SNU16, RF1, RF48 and MKN45 were obtained 
from the American Type Culture Collection (ATCC). 
Cell lines BGC823, MGC803, SGC7901, PAMC82, and 
GES were established in China. Primary GC speci-
mens and their matched normal adjacent tissues were 
collected and snap-frozen at the time of surgery. None 
of the patients had received any chemotherapy or 
radiotherapy before surgical resection. Clinical and 
histological features were obtained and evaluated 
(Table 1). Fifty peripheral blood samples were ob-
tained from healthy volunteers. The study was con-
ducted according to the Helsinki Declaration, ap-
proved by the Institutional Ethical Standards Com-
mittee of Peking University. Informed consent of all 
study subjects were obtained before the samples were 
collected.   
DNA isolation and PCR amplification 
Genomic DNA was extracted from GC cell lines, 
primary GC tissues and their matched normal gastric 
tissues, and peripheral blood samples of healthy 
volunteers. Since T889C mutation results in a new 
Taq1 site from 888 to 891 (TTGA to TCGA) in POLB 
gene, which allows us to screen for the point mutation 
by Taq1 enzyme digestion (Figure 1A). Specifically, 
we used a PCR strategy that can distinguish the 
T889C mutation from the wild-type in POLB allele. 
The primers used were: POLB Forward: 
5′-CCACTTAGGCTTATCTTTGGT-3′ and Reverse: 
5′-GGA CAC TCA CCA GTG ACT CC-3′.  
Purification of PCR products and PCR-RFLP 
analysis 
The PCR products of the expected sizes were 
purified with Geneclean Kit (Bio 101, Inc., La Jolla, 
Calif.). Ten μl of PCR products were digested with the 
restriction enzyme, TaqI (New England BioLabs, Bev-
erly, Mass.).  
PCR-DHPLC and DNA sequencing analysis 
DHPLC (denaturing high-performance liquid 
chromatography) analysis was performed as de-
scribed [16, 17]. PCR products showing aberrant 
PCR-RFLP banding patterns and exhibiting abnormal 
elution peak in DHPLC were subjected to sequencing 
analysis.  
RT-PCR assays 
Five μg of total RNA from each sample was used 
for cDNA synthesis, using the MMLV and random 
primers (Oligo dT). Two μg of reverse-transcription 
product was used as templates to amplify specific 
fragment of POLB gene. The expression of house-
keeping gene glyceraldehydes-3-phosphate dehy-
drogenase (GAPDH) was used as an internal control. 
The average relative densities of bands were detected 
by Bandlead 3.0 program. The expression level was 
shown by the ratio of POLB to GAPDH in band den-
sity. 
 
Table 1. Clinical and pathological parameters of the 177 patient 
samples used in mutation analysis 
Tissues parameters Number 
Tumor 177 
Gender  
    Male 125 
    Female 52 
Age (years)  
    Male 28-86 
    Female 29-79 
Pathology  
    Intestinal 116 
    Diffuse 30 
    Mixed 20 
    Adenosquamous 11 
Tumour location  
    GOJ * 51 
    Fundus 12 
    Greater curve-body 18 
    Lesser curve-body 11 
    Body non-specified 20 
    Antrum 65 
Differentiation   
    Well 21 
    Moderate to poor 60 
    Poor 96 
Depth of invasion  
    Mucosa 11 
    Submucosa 10 
    Muscularis propria 31 
    Serosa/full thickness 125 
No. of involved Lymph nodes  
    0 60 
    1 5 
    1-6 19 
    7-15 30 
    >15 63 
* Gastro-esophageal junction 
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Tissue microarray construction and immuno-
histochemical (IHC) staining and evaluation 
Tissue microarrays were constructed as de-
scribed previously [18]. An affinity purified goat pol-
yclonal antibody POLB (sc-5927, Santa Cruz) was 
used for IHC staining. For evaluation, the total fields 
were counted microscopically under high power 
(×200). The results of POLB expression were graded 
as: negative (-), <5% of cell stained; positive (+), >5% 
of cells stained. 
Western blot analysis 
Protein extraction and Western blot analysis 
with chemiluminescent detection were as described 
[19]. The following antibodies and dilution factors 
were used: affinity purified goat polyclonal antibody 
POLB (sc-5927, Santa Cruz, 1:800), rabbit anti-actin 
(H-196, Santa Cruz, 1:1000), donkey anti-goat 
IgG-HRP (sc-2020, Santa Cruz, 1:2000) and goat an-
ti-rabbit IgG-HRP (sc-2030, Santa Cruz, 1:2000). 
Association analysis between alterations of 
POLB gene and patients’ clinicopathological 
features, and their responses to chemotherapy 
The association between the point mutation and 
clinicopathological features such as gender, age, 
pathological diagnosis, differentiation, tumor loca-
tion, depth of invasion, liver metastasis, and lymph 
metastases was analyzed by the paired chi-square test 
with SPSS 13.0. p < 0.05 was considered statistically 
significant. 
To analyze the correlation between T889C muta-
tion and patients’ response to postoperative adjuvant 
chemotherapy, we compared progression-free time 
and overall survival time of the patients who received 
identical anticancer drug treatment, at the same 
pathological stage when initially diagnosed.  
Regarding surgical operations, patients included 
for this study must have received complete surgical 
removal of the tumor, with negative pathologic mar-
gin, and with the caveat of the anatomical location of 
the tumor and the condition of the patients. The de-
gree of surgical resection was assessed by a central 
review of operative reports, and pre- and 
post-operative imaging. When the results of scans and 
operative reports differed, the degree of surgical re-
section was assessed based on the results of computed 
tomography (CT) or magnetic resonance imaging 
(MRI). Patients with one of the following two condi-
tions were excluded: 1. underwent unsuccessful sur-
gical procedures (for instance, anastomotic leakage, 
fistula, abscess, hemorrhage); 2. had “medical” com-
plications caused by non-malignant diseases or un-
controlled infections, which were detected by the fol-
lowing examinations: CT, MRI, height, weight, com-
plete blood count, hemoglobin level, kidney/liver 
function, electrolyte levels, and calcium and magne-
sium concentrations, and a caloric intake per day by 
oral route (<1500 kcal were excluded). 
Regarding postoperative adjuvant chemothera-
py, patients eligible for the analysis should have a 
complete and detailed medical record and a report 
with gastroscopy, pathological, CT or MRI diagnosis, 
quality-of-life assessment, progression-free survival 
and overall survival time. And the information was 
obtained before chemotherapy and at specific times 
during and after drug treatment. Cases that were un-
clear whether abnormalities on postoperative scans 
represented residual tumor or postoperative artifacts, 
and cases with combination therapy of chemotherapy, 
immunotherapy and/or radiotherapy were all ex-
cluded. 
Judgments of disease relapse or progression 
were based on clinical evidence of gastroscopy, 
pathological, CT or MRI diagnosis. Patients who had 
clinical evidence of disease progression, despite scans 
indicating otherwise, were considered disease pro-
gression. The site and date of first relapse, and the 
cause and date of death were recorded. The sites of 
relapse were classified as follows: the relapse was 
coded as: loco-regional if tumor was detected within 
the operation fields (including gastric bed, remnant 
stomach, and surgical anastomosis); peritoneal if tu-
mor was detected in the peritoneal cavity; and distant 
if the metastases were diagnosed outside the perito-
neal cavity or liver metastasis. 
Real time qRT-PCR analysis 
First-strand cDNA was synthesized using the 
Bio-Rad RT kit. Primer sequences are available upon 
request. Real-time qRT-PCR assays were carried out 
on a Bio-Rad iCycler iQ system (Bio-Rad, Hercules, 
CA, USA) using SYBR Green reagent as described 
[19]. 
Construction of eukaryotic expression vector 
containing wild type and T889C mutants of 
POLB gene and transient transfection  
The entire coding region of POLB cDNA con-
taining wild type or T889C mutant, and site-directed 
mutagenesis were amplified by RT-PCR, and cloned 
respectively in a pcDNA3.1 vector before transfecting 
into AGS cells. 5 X105 cells were plated in 10 cm2 cul-
ture dishes, 25 pg of plasmid DNA/dish were trans-
fected using the calcium phosphate precipitation 
method.  
Immunofluorescence assays 
Cells were seeded at 2 × 104 cells per well on 
glass coverslips in six-well plates and fixed in 2% 
Int. J. Biol. Sci. 2015, Vol. 11 
 
 
http://www.ijbs.com 
147 
paraformaldehyde as described previously [19]. 
Confocal images were obtained using a LSM 510 
Confocal microscope (Carl Zeiss). The number of nu-
clei containing at least one localized area of immuno-
fluorescence was determined by examination of the 
confocal images. Antibodies for immunofluorescence 
were as follows: goat polyclonal antibody POLB 
(sc-5927, Santa Cruz) at final concentration of 1:800, 
Alexa Flour 568 goat anti-mouse IgG (Invitrogen), 
1:500 and Alexa Flour 568 goat anti-mouse IgG (Invi-
trogen), 1:500. 
POLB knockdown assays 
The siRNA targeting POLB was purchased from 
Qiagen (SI02663605: 5′-TACGAGTTCATCCATCA 
ATTT-3′). siRNAs against GAPDH (SI02653266 and 
SI03650325, Qiagen) were used as positive and nega-
tive controls, respectively. Cells were transfected with 
40 pmol of siRNA using the HiPerFect lipid transfec-
tion reagent (Qiagen), and harvested at 24h, 48h and 
72 h post-transfection. POLB expression was then an-
alyzed at both mRNA and protein level by qRT–PCR 
and Western blotting, respectively. 
 Chemosensitivity and MTT assays 
To determine the sensitivity of GC cell lines to 
chemotherapy, BGC823, SGC7901, AGS and N87 cells 
were seeded in a 96-well plate as described [20]. 5-FU, 
cisplatin and epirubicin were obtained from the 
pharmacy at Beijing Cancer Hospital (Beijing, China). 
Test drug concentrations were 5 to 400 µg/mL for 
5-FU, 0.5 to 8 µg/mL for cisplatin and 0.025 to 1.6 
µg/mL for epirubicin. The cells were treated by either 
single or a variety of combinations for analysis. Cells 
were seeded in a 96-well plate at the density of 3× 104 
per well, and were incubated in medium containing 
5% serum. The attached cells in the plates were 
washed once with PBS, and then replaced with fresh 
medium containing various concentrations of drugs 
to treat for 24h and 48 h. To further confirm the effect 
of the T889C on chemotherapy, the wild type, T889C 
mutant or empty vector transfected AGS cells were 
subject to MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) assays at 24h, 48h and 
72h. At each time point, 10 µl of MTT reagent 
(MILLIPORE, Billerica, MA, USA) was added to each 
well. After 4 h of incubation, cells were lysed by ad-
dition of 200 μl DMSO. Absorbance was measured at 
570 nm wavelength. Experiments were repeated three 
times, and the percentage of growth was the average 
of the experiments.  
Transwell matrigel invasion assays 
The cell line AGS transfected with wild-type and 
mutant POLB was harvested using a cell-dissociation 
solution at 90% confluence. The cells (1 × 105) were 
suspended in 100 μl of serum-free medium before 
adding to the upper chamber of the Transwell insert. 
The lower chamber was filled with 500 μl of the me-
dium with 0.1% bovine serum albumin. After 24 h of 
incubation at 37°C, the cells on the upper surface of 
the filter were removed using a cotton swab. The cells 
that penetrated to the lower surface of the filter were 
stained with hematoxylin and counted under an 
Olympus IX70 microscope (Olympus) in 13 random-
ized fields at ×400 magnification. The assay was per-
formed four times as described earlier [20, 21]. 
Plasmid treatment with UV/anticancer drugs 
and host cell reactivation (HCR) assays 
DNA repair capability of cells with wild-type 
and T889C mutant POLB were assessed using 
post-UV HCR as described previously [19] [20]. 
pCMVLuc reporter gene plasmid (a kind gift from Dr. 
Kenneth H. Kraemer, National Cancer Institute ) was 
dissolved in 10 mm Tris-HCl, 1 mm EDTA, pH 8 (TE 
buffer) to a final concentration of 100 μg/ml and 
poured in a Petri dish to form 1D 2 mm thick layer. 
The Petri dish was placed on ice and irradiated by 
1000 J/m2 of UV light. For the drug treatment, 1 μl 
aliquots of a stock solution of 1 μg / μl cisplatin, 10 μg 
/ μl 5-FU and 0.01 μg / μl cisplatin (Sigma-Aldrich, St. 
Louis, MO) in TE were added to 10 μg plasmid DNA 
before dissolving in 200 μl TE buffer, and then the 
samples were incubated at 37°C for 6 h. At the end of 
the incubation, 1 M NaCl was added to a final con-
centration of 0.2 M NaCl. The plasmid DNA was pre-
cipitated with 2 volumes of 100% ethanol, and then 
washed with 70% ethanol. The pellets were air-dried 
and dissolved in TE buffer. DNA repair capability of 
cells was assessed using HCR with the CsCl-purified 
pCMVLuc plasmid treated by UV or drugs. Four mi-
croliters (200 ng) of damaged or undamaged 
pCMVLuc were co-transfected with 0.4 µl (200 ng) of 
wild-type, and T889C mutant POLB effector plasmids 
into cells using Lipofectamine 2000 (Invitrogen). To 
estimate the DNA repair capacity after POLB knock-
down, we co-transfected pCMVLuc with 40 pmol of 
siRNA, relative luciferase activities were determined 
by a percentage of activities obtained with treated 
versus untreated control plasmids. 
Statistical analysis 
Means ± SD were calculated, and statistical 
analysis was performed using one-way ANOVA, fol-
lowed by the nonparametric Kruskal-Wallis test; p < 
0.05 was considered statistically significant. 
Protein-structure modelling 
A three-dimensional model of the L259S muta-
tion was created by comparative protein modelling 
methods [22]. The crystal structure of human POLB 
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(PDBid: 4JWM) at 2.0-Å resolution [23] was used as a 
template as justified by a 98.5% identity in amino-acid 
sequence alignment. Using the model-building pro-
gram O [24, 25], residue E256 was replaced with as-
partate to restore the active site back to that of the 
wild type, and residue L259 was replaced with serine 
to model the natural occurring mutation in cancer 
patients. The peptide backbones were not adjusted. 
Side chains were adjusted based on likelihood of 
nearby hydrogen-bonds partners within a distance of 
~3.5 Å. Protein residue numbering corresponds to the 
coding sequence within genbank accession M13140.1. 
Results 
T889C point mutation screening in a new co-
hort of GC patients 
In order to investigate the incidence of T889C 
mutation in GC, we established a new cohort of 177 
GC patients (Table 1). To facilitate large-scale T889C 
point mutation screening, a strategy based on 
PCR-RFLP was designed to characterize the mutation 
(Figure 1A). The feasibility of this strategy was firstly 
tested in 13 GC cell lines. PCR products from cell lines 
with T889C mutant POLB, BGC823, MGC803, 
SGC7901 and PAMC82 [15] were able to be cut by 
Taq1, but not for those with wild type POLB, AGS, 
N87 and MKN45. Thus, the PCR-RFLP indeed pro-
vided a reliable and simple approach for detecting the 
T889C mutation (Figure 1B). 
 
 
Figure 1. Identification of the T889C mutation in primary GCs with PCR-RFLP, DHPLC and DNA sequencing. A. Restriction analysis of the POLB gene fragment 
amplified by PCR. RFLP patterns obtained after digestion of PCR products with Taq1 endonucleases. Primers were designed to amplify the region spanning 3’ region of intron 12 
to 5’ region of exon 13 in POLB gene and length of the PCR products were 260bp. T889C mutation formed of a new Taq1 site from nucleotide 888 to 891 (TTGA to TCGA) of 
POLB (NM_002690.1) cDNA and therefore, the amplified product could be digested with Taq1. The molecular weights of digested fragments were 149bp and 111bp. B. The 
digested fragments were separated by 2.0% agarose gel electrophoresis. 100-bp ladder was used as a size marker. PCR products (260bp) amplified from BGC823, MGC803, 
SGC7901 and PAMC82 cell lines (carrying the T889C mutation) could be digested by Taq1, the molecular weights of digested fragments were 149 and 111bp while those from 
AGS, N87 and MKN45 cell lines couldn’t be digested by Taq1. C. Restriction patterns obtained by Taq1 digestion of amplified product from GC tissues. The digested fragments 
were separated by 2.0% agarose gel electrophoresis and 100bp ladder was used as a size marker. PCR products (260bp) with T889C mutation could be digested by Taq1, the 
molecular weights of digested fragments were 149 and 111bp while the PCR products with wild type POLB couldn’t be digested by Taq1. D. Chromatograph of DHPLC and 
sequencing analysis. 
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We examined 177 primary GCs. The T889C point 
mutation was detected in 18 (10.17%) of them (Figure 
1C), but not in any of the matched normal gastric tis-
sues or the 50 normal volunteer controls (Figure 1D). 
These data indicate that T889C mutation may repre-
sent an important genetic risk factor for human GCs. 
Since point mutations could alter gene function 
by either reducing (loss-of-function mutations) or 
increasing (gain-of-function mutations) its expression 
level, we examined the relationship between T889C 
mutation and expression of POLB in GC tissues. We 
constructed tissue microarrays consisting of samples 
from 70 GC patients, including 18 with- and 52 with-
out- T889C mutation, and 20 normal adjacent tissues 
(5 from patients with- and 15 without- T889C muta-
tion). The positive hybridization signals of POLB 
protein were observed in 47 (67.1%) of the 70 GCs, of 
which, 16 (88.9%) of 18 with T889C mutation, and 31 
(59.6 %) of 52 without. There was a significant positive 
association between T889C point mutation and posi-
tive signals of POLB protein (p = 0.023, Figure 2A-F 
and Supplementary Material: Table S1). The con-
cordance between T889C mutation and overexpres-
sion of POLB was confirmed by RT-PCR and Western 
blot analysis, respectively (Figure 2G & 4C). 
 
Figure 2. POLB expression on tissue array by immunohistochemistry, 
RT-PCR and Western blot analysis in GC patients.  A, B and C. With T889C 
mutation; D and E. Without T889C mutation; F. Normal tissue. G. RT-PCR (top) and 
Western blot (bottom) analysis of POLB gene in GC tissues with-T889C mutation 
(lanes 1-3) and without- (lanes 5-6). 
Association of clinicopathological features 
with T889C mutation and POLB overexpres-
sion 
We analyzed the relationship between T889C 
mutation and gender, age, tumour location, depth of 
invasion, differentiation and metastasis in 177 pri-
mary GCs. Lymph node metastases was found in all 
18 GC patients carrying T889C mutation (100%), 
whereas in 99 of the rest of the 159 patients (62.26%) . 
There were significant differences between the pa-
tients with- and without- T889C mutation in regard to 
the propensity of lymph nodes metastasis (p = 0.002, 
Supplementary Material: Table S2). GC harboring 
T889C mutation was more likely to metastasize to 
lymph nodes. Furthermore, mutation occurred in 14 
(14.58%) of 96 poorly differentiated primary GCs and 
4 (4.94%) of 81 moderately/well differentiated tumors 
(p = 0.034, Supplementary Material: Table S2). Thus 
the T889C mutation is more prevalent in poorly dif-
ferentiated primary GCs compared with those of 
moderately/well differentiated tumors. However, we 
did not find any significant correlation between 
T889C mutation and gender, age, tumour location or 
depth of invasion (p > 0.05). These findings suggest 
that T889C mutation is strongly associated with me-
tastasis and differentiation in human GC. 
We next analyzed the relationship between 
POLB expression and clinicopathological features. By 
analyzing the 70 samples on our tissue array, we 
found that POLB positivity was not associated with 
lymph nodes metastasis, poorly differentiation, age, 
gender, tumour location and depth of invasion (p > 
0.05), despite that T889C mutation was significantly 
associated with poor differentiation (p = 0.009) and 
lymph nodes metastasis (p = 0.018). Our data sug-
gested that POLB expression alone is not associated 
with clinicopathological features.  
T889C mutation is associated with the re-
sponse to postoperative chemotherapy 
POLB plays a significant role in chemotherapeu-
tic agent resistance [26]. Among the 177 cases, 143 
patients received postoperative adjuvant chemother-
apy. Nineteen GC patients were analyzed to reveal 
the relationship between the mutation and the re-
sponse to postoperative chemotherapy as they were 
diagnosed at the same clinicopathological stage) be-
fore surgery, and treated with the same anticancer 
drugs/doses. They were all at stage T4N2M0, and 
treated with cisplatin (60 mg / m2 i.v.) and epirubicin 
(50 mg / m2 i.v.), every 3 weeks for four cycles to-
gether with a continuous 12 week infusion of 5-FU 
(200 mg / m2 /day). The estimated median progres-
sion-free and overall survival times were 11±1.405 and 
16±4.265 months, respectively. Significant differences 
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in progression-free and survival time were found 
between patients with T889C mutation (8) and those 
without the mutation (11) (p=0.026), and significant 
difference also existed in overall survival (16±4.265 vs. 
24±8.34, p=0.027) between the two groups (Figure 
3A&B). Patients with T889C mutation had signifi-
cantly shorter survival than those without the muta-
tion following chemotherapy. Our data indicates that 
T889C mutation is associated with poor response to 
postoperative chemotherapy. 
To further examine the relationship between al-
ternative POLB and poor response to anticancer 
drugs, we assessed the sensitivity of cell lines 
BGC823, SGC7901, AGS and N87 to the single-agent 
and combinations of 5-FU, cisplatin and epirubicin by 
MTT assays. We found that the cell lines with T889C 
mutation (BGC823, SGC7901) were more resistant to 
5-FU, cisplatin and epirubicin than those with wild 
type POLB (Figure 4A&B). These results support the 
clinical observation that T889C mutation is associated 
with poor response to postoperative chemotherapy. 
 
Figure 3. Correlation between T889C mutation and survival. Progres-
sion-free survival (top) and overall survival (bottom) for all 19 patients enrolled. The 
statistical significance of the difference was p = 0.027 and p = 0.026. Patients with 
T889C mutation had significantly shorter survival than did patients without the 
mutation after postoperative chemotherapy. 
Overexpression of POLB gene stimulates pro-
liferation and promotes invasion and migra-
tion in human GC cell lines 
Having demonstrated the relationship between 
T889C mutation, and lymph node metastasis and dif-
ferentiation in clinical samples, we further examined 
the role of T889C mutation in metastasis, differentia-
tion and resistance to anticancer drugs in GC cell 
lines. Relative POLB mRNA and protein levels in 
transfected AGS cell lines with wild type or T889C 
were significantly increased (p<0.01) than that of the 
vector control lines, and the receptor genes expressing 
both the wild-type and mutant were localized to the 
nucleus (Figure 5A). We compared the number of 
cells expressing wild type or mutated POLB at 24, 48 
and 72 h after transfection. The number of mutant 
POLB-transfected cells increased more significantly 
than that of the wild-type (Figure 5B). Conversely, 
knockdown of POLB by siRNA resulted in a de-
creased cell growth in AGS cells. Our data suggested 
that cells transfected with T889C mutated POLB in-
creased cell proliferation. Next, we examined the in-
vasive and spontaneous metastatic potential by mat-
rigel assays. The invasion of the mutant 
POLB-transfected cells was significantly increased 
compared with the wild type POLB-transfected cells. 
In addition, knockdown of POLB by siRNA reduced 
cell growth in AGS cells (Figure 5C). These results 
suggest that GC cells with T889C mutation are more 
proliferative and invasive.  
Expression of POLB with T889C mutation 
leads to resistance to chemotherapeutic 
agents 
In order to further elucidate relationship be-
tween T889C mutation and resistance to chemother-
apy, we transfected the AGS cell line with either wild 
type or T889C mutated POLB, and treated them with 
various concentrations of anticancer drugs. We found 
that cells transfected with T889C mutant were signif-
icantly more resistant to cisplatin and 5-FU compared 
to those transfected with empty vectors (Figure 5D). 
Inhibition of POLB expression by siRNA restored 
chemosensitivity in AGS cells. Our data further cor-
roborates that T889C mutation correlated with poor 
response to postoperative chemotherapy. 
Overexpression of POLB with T889C mutation 
significantly increased post-drugs host cell re-
activation activity in GC cell line 
POLB participates in regulation of DNA repair 
during carcinogen exposure [8]. We then asked 
whether overexpression of POLB increases the re-
sistance of the GC cell lines to anticancer drugs via 
DNA repair pathway. We measured the luciferase 
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activity by co-transfecting wild type or T889C mutant 
POLB, along with pCMU-Luc vector [19], which was 
pre-treated by anticancer drugs respectively, into the 
AGS cell line. We found that AGS exhibited signifi-
cantly increased luciferase activity when the 
pCMU-Luc vector was treated with cisplatin and 
5-FU. There was no difference in luciferase activity 
when the pCMU-Luc vector was treated with epiru-
bicin (Figure 5E). Our data indicate that the T889C 
mutation enhances the DNA repair capability in GC 
cell line. 
When co-transfected AGS with POLB siRNA and 
pCMU-Luc vector pre-treated with anticancer drugs, 
DNA repair capability was decreased when 
pre-treated with cisplatin and 5-FU. However, there 
were no significant DNA repair capability changes 
when co-transfected with POLB siRNA and 
pCMU-Luc vector pre-treated with epirubicin. These 
data demonstrate that the T889C mutation exerts a 
distinct effect on DNA repair toward anticancer 
drugs, such as cisplatin and 5-FU, but not epirubicin 
in GC cell line. Therefore, T889C mutation may be a 
gain-of-function mutation affecting chemotherapy 
response via DNA repair pathway. 
 
Figure 4. Correlation between T889C mutation and cytotoxicity of 5-fluorouracil, cisplatin and epirubicin. A. Phenotypic comparison of BGC823, SGC7901 and 
AGS cell lines before and after treatment. B. Sensitivity of cell lines to cisplatin, epirubicin, 5-fluorouracil and combination treatment with three drugs. Concentration of 
5-fluorouracil, cisplatin, epirubicin, and was 5ug/ml, 0.5ug/ml and 0.1ug/ml respectively. The concentration of combination treatment of three drugs is cisplatin 0.5ug/ml, epirubicin 
0.1ug/ml, and 5-fluorouracil 5ug/ml. Survival is expressed as the relative plating efficiency of treated cells to the control. The values shown in the figures are mean readings from 
six wells in each experiment and representative of at least three independent experiments. C. Protein expression of POLB in cell lines BGC823, SGC7901, AGS and N87. 
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A hypothetical model of the human POLB with 
T889C mutation 
To elucidate the possible mechanism of the 
POLB T889C mutation associated functional changes, 
we modeled its protein crystallographic structure. The 
T889C mutation in the nucleotide sequence of gen-
bank accession M13140.1 would result in an encoded 
serine at residue position 259 that would be in hy-
drogen-bonding proximity to carboxyl groups of res-
idues 232 and 233 on the backbone chain in an adja-
cent β-strand (Figure 6). These interactions would 
distort the β-strand where the serine resides resulting 
in a positional shift of the catalytic residue, D256. In 
wild type, D256 is stabilized by one of the two bound 
metal ions (Mg2+) and is thought to deprotonate the 
O3' group of the primer or newly forming DNA 
strand during synthesis [23]. A change in the active 
site could either result in a lower activation barrier for 
catalysis or simply loosen the constraints in the active 
site for the DNA strand to pass with greater flexibility 
and speed. There may be additional precedence for a 
more efficient active site as other hydrophobic sub-
stituted residues, now capable of electrostatic interac-
tions, are also present around the active site, such as 
L228R, I260Y, and possibly L287K when comparing 
genbank accession number M13140.1  with 
AAA60133.1 used in our model (PDBid:4JWM).  
 
 
Figure 5. The effect of POLB overexpression. AGS cells were transfected with empty pcDNA3.1, wild type POLB, T889C mutant and POLB siRNA. A. Expression of 
transfected POLB genes in human GC cell lines. Left panel, representative results of the QRT-PCR analysis of POLB mRNA levels in AGS cell lines. Each reaction was run twice 
in triplicates. POLB expression was normalized by GAPDH. Right panel, representative results of the Immunofluorescence for POLB protein expression. POLB protein of both the 
wild-type and mutant localized to the nucleus. B. The effect of POLB wild type, mutant and siRNA in AGS cell proliferation. MTT assays indicate cell proliferation rate was 
significantly higher in T889C overexpressors (left). The experiments were done three times in triplicates. Right panel shows phenotypic comparison of AGS cell lines before and 
after transfection of POLB wild type and mutant and siRNA. C. Matrigel analysis. Three fields of unit area on each membrane were counted for cell numbers, and the experiments 
were repeated twice. Data analysis was based on the average of parallel repeats. T889C mutation overexpressing cell lines exhibited very significantly higher invasiveness than 
wild type and empty vector control cell lines. D. Resistance assay. The cells were treated with or without 5-fluorouracil, cisplatin, and epirubicin for 24 h. The values are 
represented as a mean from three separate experiments; bars, ±SD. E. HCR assay showing increased post-UV DNA repair capability in T889C overexpressors. *p < 0.05. 
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Figure 6. A hypothetical model of the human POLB enzyme is shown in complex with DNA, and containing the L259S mutation that is found commonly 
in gastric cancer patients. The two known metal ions bound in the active site are shown as magenta spheres. A. The entire enzyme is shown revealing the relative location 
of the serine in proximity to the active site. B. A close-up view of additional hydrogen-bond networks is shown in a β-sheet that would lead to a predicted small distortion in the 
active site. The figure was made with the program, MOLSCRIPT [38]. 
 
Discussion 
This study presents a comprehensive picture of 
the T889C mutation in POLB gene and its expression 
in relation with GC patients’ clinicopathological fea-
tures. We deciphered the functional relationship be-
tween mutant and wild type POLB gene, in associa-
tion with DNA repair pathway. The T889C mutation 
was associated with POLB overexpression, clinico-
pathological features, such as lymph node metastasis 
and differentiation, and response to chemotherapy. 
Our clinical and experimental data indicate an onco-
genic property in mutant POLB gene in comparison to 
the wild type POLB gene in GC. Previous study sug-
gested that POLB exhibits dichotomous functions 
depending on its expression, either as an oncogene or 
as a tumor suppressor [27-30]. Our data indicate that 
T889C mutation in POLB is a relatively frequent 
phenomenon and this may be an underlying mecha-
nism for gastric cell mutagenesis via enhanced DNA 
repair pathway. There are two possible reasons where 
the L259S substitution may arise naturally. First, it 
could allow for higher expression levels. We found a 
significant positive association between T889C muta-
tion and overexpression of POLB gene. However, the 
exact mechanism by which T889C mutation leads to 
POLB gene overexpression is not clear. We hypothe-
size that epigenetic factors may be involved, which 
would be our direction for future investigation. Se-
cond, beyond epigenetics, a serine substitution could 
conceivably increase the specific activity of the poly-
merase in crisis. Detailed X-ray crystallographic 
studies are needed to determine the effects of the 
substitutions in the active site. 
DNA repair and the fidelity of DNA relegation 
have been found to be correlated with metastatic po-
tential [31-33]. We discovered that T889C mutation, 
but not POLB overexpression alone, was significantly 
correlated to increased lymph nodes metastasis. Our 
data suggests that abnormally enhanced DNA repair 
capability increases the risk of tumor metastasis for 
GC.  
Previous studies suggested that POLB may play 
a fundamental role in cellular differentiation [34, 35]. 
Our results further demonstrated that poor-
ly-differentiated tumors carried higher frequency of 
T889C mutation than moderately/well differentiated 
tumors. We hypothesize that the poor differentiation 
associated with T889C mutation may be due to the 
disruption of DNA repair synthesis or DNA transla-
tion synthesis during differentiation, or by facilitating 
accumulation of mutations in differentiation-related 
genes. 
POLB has been found to efficiently bypass the 
cisplatin adduct [36]. Studies showed that abnormal 
POLB expression associated with the cytotoxic effects 
of DNA damaging chemotherapeutic agents [37]. In 
this study, we showed that T889C mutation of POLB 
gene was correlated closely with a poor response to 
5-FU, cisplatin and epirubicin in GC patients. It is 
suggested that T8889C mutation might facilitate cell 
survival by enhancing DNA repair capability, to by-
pass various DNA damages by commonly used 
chemotherapeutic drugs.  
Conclusions 
The T889C mutation in POLB gene is a prevalent 
event among GC patients. The alteration of POLB 
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gene mutation and expression is associated with the 
pathological features including differentiation, lymph 
nodes metastasis, and poor prognosis via DNA repair 
pathway. Thus, the POLB gene with T889C mutation 
in surgically resected primary gastric tissues may be 
clinically useful for predicting responsiveness to 
chemotherapy in patients with GC. The POLB gene 
alteration may serve as a prognostic biomarker for 
GC. 
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